JP2017538443A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538443A5
JP2017538443A5 JP2017543328A JP2017543328A JP2017538443A5 JP 2017538443 A5 JP2017538443 A5 JP 2017538443A5 JP 2017543328 A JP2017543328 A JP 2017543328A JP 2017543328 A JP2017543328 A JP 2017543328A JP 2017538443 A5 JP2017538443 A5 JP 2017538443A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
hmyd88
amino acids
sequence variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538443A (ja
JP6898244B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/059510 external-priority patent/WO2016073875A1/en
Publication of JP2017538443A publication Critical patent/JP2017538443A/ja
Publication of JP2017538443A5 publication Critical patent/JP2017538443A5/ja
Application granted granted Critical
Publication of JP6898244B2 publication Critical patent/JP6898244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543328A 2014-11-06 2015-11-06 CD8αおよびT細胞受容体の変異体ならびに免疫細胞の応答の調節においてそれらを使用する方法 Active JP6898244B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076120P 2014-11-06 2014-11-06
US62/076,120 2014-11-06
US201562130092P 2015-03-09 2015-03-09
US62/130,092 2015-03-09
PCT/US2015/059510 WO2016073875A1 (en) 2014-11-06 2015-11-06 CD8α AND T CELL RECEPTOR VARIANTS AND METHODS OF USING SAME IN MODULATING IMMUNE CELL RESPONSES

Publications (3)

Publication Number Publication Date
JP2017538443A JP2017538443A (ja) 2017-12-28
JP2017538443A5 true JP2017538443A5 (enExample) 2018-11-29
JP6898244B2 JP6898244B2 (ja) 2021-07-07

Family

ID=55909872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543328A Active JP6898244B2 (ja) 2014-11-06 2015-11-06 CD8αおよびT細胞受容体の変異体ならびに免疫細胞の応答の調節においてそれらを使用する方法

Country Status (6)

Country Link
US (1) US10975137B2 (enExample)
EP (1) EP3215521B1 (enExample)
JP (1) JP6898244B2 (enExample)
AU (1) AU2015342867B2 (enExample)
CA (1) CA2966858A1 (enExample)
WO (1) WO2016073875A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7529265B2 (ja) 2018-04-19 2024-08-06 ベイラー カレッジ オブ メディスン CD8abおよびクラス1制限T細胞受容体の強制発現による細胞傷害性CD8細胞へのCD4 T細胞の再プログラミング
AU2020264484A1 (en) 2019-05-01 2021-11-04 Adoc Ssf, Llc Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
KR102152189B1 (ko) * 2020-02-11 2020-09-04 재단법인 아산사회복지재단 T 세포 내 표적 위치로의 t 세포 수용체 삽입을 위한 재조합벡터 및 이를 이용한 t 세포 내 표적 위치로의 t 세포 수용체 삽입용 조성물
US20230310606A1 (en) * 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
DK2331680T3 (en) * 2008-09-22 2017-08-21 Baylor College Medicine Methods and Compositions for Generating an Immune Response by Induction of CD-40 as well as Pattern Recognition Receptor Adapters
EP2558109A4 (en) * 2010-04-16 2014-09-24 Bellicum Pharmaceuticals Inc METHOD FOR TREATING HARD TUMORS
CA3209571A1 (en) * 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
BR112015000310A2 (pt) * 2012-07-13 2017-06-27 Univ Pennsylvania conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car
WO2014039961A1 (en) * 2012-09-07 2014-03-13 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014099671A1 (en) * 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
JP6868554B2 (ja) * 2014-09-02 2021-05-12 ベリカム ファーマシューティカルズ, インコーポレイテッド MyD88およびCD40ポリペプチドによるキメラ抗原受容体の共刺激

Similar Documents

Publication Publication Date Title
JP2017538443A5 (enExample)
EA202190669A1 (ru) Процесс получения вакцинной композиции
CY1119792T1 (el) Βασισμενη σε πρωτεϊνες θεραπεια και διαγνωση tau-διαμεσολαβουμενης παθολογιας σε νοσο του alzheimer
JP2014510519A5 (enExample)
JP2019511222A5 (enExample)
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
JP2011502479A5 (enExample)
JP2016529229A5 (enExample)
JP2013107899A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
JP2018528237A5 (enExample)
RU2013114424A (ru) Полипептиды гемагглютининов, а также связанные с ними реагенты и способы
JP2017514522A5 (enExample)
JP2019530441A5 (enExample)
RU2016107873A (ru) Пептиды
JP2016513956A5 (enExample)
RU2018105007A (ru) Композиции против аллергии на кошек
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа